1g7p › Citations

Crystal structure of a non-canonical high affinity peptide complexed with MHC class I: a novel use of alternative anchors.

Apostolopoulos V, Yu M, Corper AL, Li W, McKenzie IF, Teyton L, Wilson IA, Plebanski M
J Mol Biol 318 1307-16 (2002)
Cited: 27 times
EuropePMC logo PMID: 12083519

Abstract

The crystal structure of a non-standard peptide, YEA9, in complex with H-2Kb, at 1.5 A resolution demonstrates how YEA9 peptide can bind with surprisingly high affinity through insertion of alternative, long, non-canonical anchors into the B and E pockets. The use of "alternative pockets" represents a new mode of high affinity peptide binding, that should be considered when predicting peptide epitopes for MHC class I. These novel interactions encountered in this non-canonical high affinity peptide-MHC complex should help predict additional binding peptides from primary protein sequences and aid in the design of alternative approaches for peptide-based vaccines.

Articles - 1g7p mentioned but not cited (7)

  1. Structural comparison of allogeneic and syngeneic T cell receptor-peptide-major histocompatibility complex complexes: a buried alloreactive mutation subtly alters peptide presentation substantially increasing V(beta) Interactions. Luz JG, Huang M, Garcia KC, Rudolph MG, Apostolopoulos V, Teyton L, Wilson IA. J Exp Med 195 1175-1186 (2002)
  2. Modeling the structure of bound peptide ligands to major histocompatibility complex. Tong JC, Tan TW, Ranganathan S. Protein Sci 13 2523-2532 (2004)
  3. pDOCK: a new technique for rapid and accurate docking of peptide ligands to Major Histocompatibility Complexes. Khan JM, Ranganathan S. Immunome Res 6 Suppl 1 S2 (2010)
  4. Prediction and identification of T cell epitopes in the H5N1 influenza virus nucleoprotein in chicken. Hou Y, Guo Y, Wu C, Shen N, Jiang Y, Wang J. PLoS One 7 e39344 (2012)
  5. An unbiased approach to defining bona fide cancer neoepitopes that elicit immune-mediated cancer rejection. Brennick CA, George MM, Moussa MM, Hagymasi AT, Seesi SA, Shcheglova TV, Englander RP, Keller GL, Balsbaugh JL, Baker BM, Schietinger A, Mandoiu II, Srivastava PK. J Clin Invest 131 142823 (2021)
  6. Improved pan-specific MHC class I peptide-binding predictions using a novel representation of the MHC-binding cleft environment. Carrasco Pro S, Zimic M, Nielsen M. Tissue Antigens 83 94-100 (2014)
  7. Structural Analyses of a Dominant Cryptosporidium parvum Epitope Presented by H-2Kb Offer New Options To Combat Cryptosporidiosis. Wang Y, Gao M, Li X, Zhu W, Zhao M, Li J, Liu X, Cao L, Li S, Zhang S, Zhang L, Fan S. mBio 14 e0266622 (2023)


Reviews citing this publication (4)

  1. Recognition of open conformers of classical MHC by chaperones and monoclonal antibodies. Hansen TH, Lybarger L, Yu L, Mitaksov V, Fremont DH. Immunol Rev 207 100-111 (2005)
  2. Strategies used for MUC1 immunotherapy: preclinical studies. Tang CK, Apostolopoulos V. Expert Rev Vaccines 7 951-962 (2008)
  3. Noncanonical peptides in complex with MHC class I. Apostolopoulos V, Lazoura E. Expert Rev Vaccines 3 151-162 (2004)
  4. Peptide-based vaccines for cancer: are we choosing the right peptides? Apostolopoulos V. Expert Rev Vaccines 8 259-260 (2009)

Articles citing this publication (16)



Quick links